SEC Filing Summary: AspenBio Pharma, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AspenBio Pharma, Inc. on May 24, 2012, regarding events occurring at the Company's Annual Meeting of Shareholders held on May 22, 2012. The filing details the results of shareholder votes on director elections, stock plan amendments, and capital structure changes. Note: The request metadata referenced "Riot Platforms, Inc."; however, the source text explicitly identifies the registrant as AspenBio Pharma, Inc.
Key Financial Metrics
This filing is a corporate governance report and does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only quantitative data presented relates to share counts and voting results.
Material Changes and Shareholder Actions
Shareholders representing 3,368,459 of the 9,633,321 outstanding shares voted on three primary matters:
- Director Elections: Nine directors were elected to serve until the 2013 Annual Meeting. All nominees received significant majority support, with vote counts ranging from approximately 3.19 million to 3.22 million votes "For."
- Stock Incentive Plan Amendment: Shareholders approved an amendment to the 2002 Stock Incentive Plan, increasing the number of reserved shares from 1,500,000 to 1,775,000. The vote was 3,068,487 "For" versus 293,890 "Against."
- Reverse Stock Split Authorization: Shareholders authorized a reverse stock split of the Company's Common Stock in a ratio of at least 1-for-2 and up to 1-for-6. This included an amendment to the Articles of Incorporation. The vote was 3,105,747 "For" versus 250,702 "Against."
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. No specific risks or contingencies were disclosed in this report, other than the inherent corporate action of the authorized reverse stock split, which remains subject to the Board of Directors' authority to abandon the amendment.
Investor Verification Checklist
- Verify the implementation date and specific ratio of the authorized reverse stock split (1-for-2 to 1-for-6).
- Confirm the impact of the increased stock incentive plan reserve (1,775,000 shares) on potential future dilution.
- Review subsequent filings to determine if the Board exercises its option to abandon the reverse stock split amendment.
- Check for updated financial statements in the next 10-Q or 10-K filing, as this 8-K contains no financial performance data.